Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

BACKGROUND: AVT02 (adalimumab) is a proposed biosimilar to Humira(®). AVT02 is produced at a 100 mg/mL concentration with a citrate-free formulation. OBJECTIVES: The aim of this study was to compare the efficacy, safety and immunogenicity of AVT02 versus Humira(®) in subjects with moderate to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Feldman, Steven R., Reznichenko, Nataliya, Pulka, Grazyna, Kingo, Külli, George Galdava, Berti, Fausto, Sobierska, Joanna, Dias, Roshan, Guenzi, Eric, Hendrik Otto, Haliduola, Halimu N., Kay, Richard, Stroissnig, Heimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520467/
https://www.ncbi.nlm.nih.gov/pubmed/34657274
http://dx.doi.org/10.1007/s40259-021-00502-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520467/
https://www.ncbi.nlm.nih.gov/pubmed/34657274
http://dx.doi.org/10.1007/s40259-021-00502-w

Ejemplares similares